In order to match the improved titers and yield Innovation has provided, many biopharmaceutical companies are re-evaluating the operational costs of stainless steel and exploring the economics of single-use systems.
While the Biosimilar market is expected to reach $20B by 2020, four factors will play a major influence on just how quickly the biosimilar market will grow: patent expirations, regulatory pathways, development challenges and viability of a commercial model.
As the adoption and maturation of single-use technologies continues to evolve, many end-users are looking for single-use suppliers to standardize products, materials, and equipment in order to improve efficiency and lower costs. An expert group of industry suppliers discusses the pros/cons and differing expectation surrounding this trend.
No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. The XS System™ ultimately decreases the time of strain screening and design to enable the fast creation of a valuable production strain and efficient cGMP process.